Announcement from the annual general meeting held on June 28, 2022 in Biosergen AB
Biosergen AB held its annual general meeting on June 28, 2022. The meeting was conducted by postal voting only, without any physical attendance. For more detailed information on the resolutions, please refer to the full notice and the complete proposals. The main resolutions passed at the meeting were as follows:
Adoption of the income statements and the balance sheets
The meeting resolved to adopt the income statement and the balance sheet for the parent company as well as the consolidated income statement and the consolidated balance sheet for the group for 2021.
Disposition of the company's earnings
The meeting resolved, in accordance with the board’s proposal, to carry forward available funds, to a new account and that no dividend shall be paid for the financial year 2021.
Discharge from liability
The members of the board of directors and the CEO were discharged from liability for the financial year 2021.
Board of directors and auditor
The meeting resolved, in accordance with shareholders’ proposal, that the board shall be composed of seven directors without deputies. The meeting further resolved, in accordance with shareholders’ proposal, on the re-election of directors Torsten Goesch, Lena Degling Wikingsson, Achim Kaufhold, Mattias Klintemar, Marianne Kock, Hanne Mette Dyrlie Kristensen and Henrik Moltke. Torsten Goesch was re-elected as chairman of the board.
The meeting resolved, in accordance with shareholders’ proposal, that fees to the members of the board of directors shall, for a full year, amount to EUR 40,000 to the chairman of the board and EUR 25,000 to each of the other board members elected by the general meeting who are not employed by the company.
The registered accounting firm Öhrlings PricewaterhouseCoopers AB was re-elected as auditor for the period up until the end of the next annual general meeting. It was resolved that remuneration to the auditor shall be paid according to approved invoices.
Resolution on an issue authorisation
The meeting resolved, in accordance with the board’s proposal, on an issue authorisation for the board of directors to, on one or more occasions up until the next annual general meeting, resolve on issue of shares, convertibles, warrants, and/or a combination of these, so-called units. Issue can be made with or without deviation from the shareholders' pre-emption rights.
This authorisation includes the right to issue shares, convertibles, warrants and/or units, with cash payment, payment by way of set-off or payment by contribution in kind, and otherwise subject to conditions as set out in Chapter 2, section 5, second paragraph 1–3 and 5 of the Swedish Companies Act. Warrants may be issued without consideration.
For further information, please contact:
Dr. Peder M. Andersen, CEO
+45 2080 2470
peder.andersen@biosergen.net
Certified Adviser
Erik Penser Bank
+46 8 463 8000
certifiedadviser@penser.se
ABOUT BIOSERGEN
Biosergen is a clinical stage biotechnology company that employs all its organisational and financials resources on the clinical development of BSG005. BSG005 is a potentially disruptive antifungal drug with blockbuster potential based on significant safety and potency advantages over competing antifungals, including Amphotericin B, in more than a decade of preclinical studies. The research behind BSG005 and its unique properties has been documented in over 20 peer reviewed scientific papers. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS-, cancer- and transplant patients every year. At equal dose levels BSG005 shows a three-to-fourfold potency advantage against relevant fungal strains compared to current standards of care, while being completely free of the kidney toxicity hampering other drugs in its class. The Company is also developing BSG005 Nano where the drug is packed in special nano particles to specifically target the lung, often the first affected organ in an invasive fungal infection. BSG005 Nano Oral is an extension of BSG005 Nano. An oral formulation would greatly increase the usefulness, particularly as a prophylactic and as home treatment after transplants or cancer treatment to prevent invasive fungal infection. Biosergen has received orphan drug status for BSG005 in the United States.